Article

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

2020-06-23

Abstract excerpt

<h4>Background</h4> Health state utility values (HSUVs) identified from utility elicitation studies are widely used in pharmacoeconomic evaluations for chronic hepatitis C (CHC) and are particularly instrumental in health technology assessment (HTA) evaluation like the National Institute for Health and Clinical Excellence (NICE). <h4>Objective</h4> The objective of this study is to identify HSUVs used in cost-util...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 819858ca-db74-5124-9aee-1f11fab91785
DOI: 10.1101/2020.06.22.20135434

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness resultsDOI 10.1101/2020.06.22.20135434Read

A Study on Health Utility Mapping Model of the Generalized Quality of Life Measurement Scale with Chinese Medicine CharacteristicsSemantic proximity Read

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read

Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysisSemantic proximity Read

Using the OPUF approach to create a value set for the EQ-HWB-S: An exploratory feasibility studySemantic proximity Read

The Economic Impact of National Essential Public Health Service Package for Hypertension and Type-2 Diabetes: A Retrospective Province-wide Study in ChinaSemantic proximity Read

Value-based genomic screening: exploring genomic screening for chronic diseases using triple value principles.Semantic proximity Read

Longitudinal Changes in Utilities and HRQoL During Interferon‑Free DAA Therapy for Chronic Hepatitis C in Japan: Implications for Cost‑Utility AnalysisSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesSemantic proximity Read

Projected burden of alcohol-associated liver disease in China, 2020-2050: A microsimulation modeling studySemantic proximity Read